For the Quarter Ending December 2025
North America
• In the USA, the Etoricoxib Price Index rose by 1.59% quarter-over-quarter, reflecting reduced Chinese exports and freight pressures.
• The average Etoricoxib price for the quarter was approximately USD 69188.33/MT on a CFR Houston basis.
• Etoricoxib Spot Price firmed early quarter as USD weakening versus CNY and freight increases elevated landed import costs.
• Etoricoxib Price Forecast indicates modest declines into December due to inventory consolidation and softer trial-related offtake.
• Etoricoxib Production Cost Trend was eased by falling Asia-US freight rates, marginally reducing landed cost pressure.
• Etoricoxib Demand Outlook remains narrow, driven by academic trials and compassionate-use imports, limiting broad pharmaceutical uptake.
• Etoricoxib Price Index movements reflected balanced distributor inventories, steady exports from India, and selective buyer purchasing patterns.
• Major supplier operations remained routine with no maintenance-related shutdowns, supporting continuous parcel-sized shipments into Houston.
Why did the price of Etoricoxib change in December 2025 in North America?
• Easing freight rates lowered landed costs, directly reducing import offers for parcel-sized Etoricoxib consignments into the US.
• Soft trial-related offtake and subdued restocking constrained demand, allowing distributors to run higher inventories without urgent purchases.
• Stable foreign factory production and lack of domestic capacity kept supply ample, pressuring Etoricoxib Price Index downward modestly.
APAC
• In China, the Etoricoxib Price Index rose by 1.4% quarter-over-quarter, driven by seasonal export recovery.
• The average Etoricoxib price for the quarter was approximately USD 68983.33/MT, reflecting stable export demand.
• Etoricoxib Spot Price showed mild softness in December amid subdued overseas buying and destocking activity.
• Etoricoxib Price Forecast indicates modest recovery in early 2026 as buyers gradually replenish post-holiday inventories.
• Etoricoxib Production Cost Trend shows modest upward pressure from wastewater compliance and fluorinated intermediate costs.
• Etoricoxib Demand Outlook remains cautious as VBP tender timing encourages hospitals to delay spot purchases.
• Etoricoxib Price Index pressure stemmed from ample finished-goods inventories and muted export inquiries from India, Brazil.
• Major Zhejiang and Jiangsu plants operated near nameplate capacity, keeping flows, limiting Etoricoxib Price Index volatility.
Why did the price of Etoricoxib change in December 2025 in APAC?
• Reduced buyer urgency and VBP tender uncertainty led to subdued offtake from hospitals and overseas formulators.
• Higher wastewater compliance and fluorinated intermediate monitoring increased costs, pressuring margins but not restricting output.
• Efficient port logistics and freight prevented delays, while firmer CNY reduced overseas arbitrage and enthusiasm.
Europe
• In Germany, the Etoricoxib Price Index rose by 1.43% quarter-over-quarter, reflecting mild restocking and firmer offers.
• The average Etoricoxib price for the quarter was approximately USD 69066.67/MT, based on shipment-weighted data.
• Etoricoxib Spot Price movements remained subdued amid steady Indian exports and comfortable bonded warehouse inventories.
• Etoricoxib Price Forecast points to modest near-term softness, followed by selective restocking in January 2026.
• Etoricoxib Production Cost Trend saw limited pressure as freight and feedstock costs remained neutral overall.
• Etoricoxib Demand Outlook stays steady with balanced pharmaceutical offtake and conservative wholesaler purchasing patterns currently.
• Price Index volatility was low, reflecting balanced supply, disciplined buyers, and routine regulatory release timing.
• Inventory coverage at German bonded warehouses supported liquidity while Hamburg operations remained fully operational throughout.
Why did the price of Etoricoxib change in December 2025 in Europe?
• Steady Indian exports and ample distributor stocks reduced urgency, softening landed offers and keeping prices muted.
• Year-end buying cycles remained subdued as wholesalers drew down earlier purchases, limiting fresh procurement thereby.
• Stable freight costs and neutral currency movements reduced landed-cost pressure; regulatory release delays extended lead times.
For the Quarter Ending September 2025
North America
• In USA, the Etoricoxib Price Index fell by 15.27% quarter-over-quarter, driven by excess imports and weak demand.
• The average Etoricoxib price for the quarter was approximately USD 68105/MT, reflecting CFR Houston trade patterns.
• Etoricoxib Spot Price softened amid elevated inventories and aggressive Asian export offers pressuring domestic quotations.
• Etoricoxib Price Forecast indicates initial July declines then modest recovery as restocking gradually resumes later.
• Etoricoxib Production Cost Trend showed downward pressure from lower landed costs offset by freight variations.
• Etoricoxib Demand Outlook remains subdued with weak pharmaceutical procurement and cautious downstream manufacturing activity levels.
• Etoricoxib Price Index movement reflected high inventories, softer consumption, and exporter pricing dynamics pressuring offers.
• Etoricoxib Spot Price sensitivity increased due to tariff uncertainty, freight volatility, and shifting import competitiveness.
Why did the price of Etoricoxib change in September 2025 in North America?
• Excess supply from reduced Asian export prices and high inventories pressured prices and procurement activity.
• Declining demand from pharmaceutical formulators and cautious downstream restocking limited upward price momentum despite signals.
• Freight rate fluctuations and tariff uncertainty altered landed costs, influencing import decisions and price dynamics.
APAC
• In China, the Etoricoxib Price Index fell by 15.28% quarter-over-quarter, reflecting inventories and weak export demand.
• The average Etoricoxib price for the quarter was approximately USD 68000/MT based on export shipments.
• Etoricoxib Spot Price firmed as Etoricoxib Production Cost Trend reflected raw material and freight expenses.
• Etoricoxib Price Forecast for September indicated gains driven by domestic replenishment and steady factory rates.
• Etoricoxib Demand Outlook improved slightly with pharmaceutical offtake supporting volumes despite weak international purchase momentum.
• Etoricoxib Price Index pressure persisted from high inventories and subdued export inquiries, limiting seller pricing power.
• Resumed output after scheduled plant maintenance combined with aggressive stock clearance kept market selling activity soft.
• Higher freight rates and currency shifts eroded export competitiveness, reducing inbound orders and pressuring margins.
Why did the price of Etoricoxib change in September 2025 in APAC?
• Elevated inventories reduced buying urgency, prompting suppliers to cut offers to clear aged stock quickly.
• Weak overseas orders combined with higher freight and tariff uncertainty diminished export demand and price support.
• Input cost declines earlier relieved manufacturing costs, but resurgent raw material inflation partially offset downward pressures.
Europe
• In Germany, the Etoricoxib Price Index fell by 15.26% quarter-over-quarter, reflecting weak demand and inventory.
• The average Etoricoxib price for the quarter was approximately USD 68090.00/MT, reported by German importers.
• Etoricoxib Spot Price remained subdued amid Chinese export discounts and ample domestic inventories, limiting buyers.
• Etoricoxib Price Forecast indicates mild recovery in coming months driven by restocking and downstream demand.
• Etoricoxib Production Cost Trend eased slightly with lower Asian export offers and softer raw materials.
• Etoricoxib Demand Outlook remains weak as pharmaceutical buyers defer orders amid high inventories, limiting procurement.
• Inventory overhang and muted export demand pressured Etoricoxib Price Index, prompting competitive seller discounts persistently.
• Major suppliers operated near-normal output, sustaining availability while selective restocking provided upward pressure on prices.
Why did the price of Etoricoxib change in September 2025 in Europe?
• Excess inventory and aggressive Asian export discounts reduced landed costs, exerting downward pressure on prices.
• Freight rate fluctuations and currency moves eased import expenses but higher shipping costs constrained procurement.
• Weak pharmaceutical and healthcare demand, combined with supplier discounts, discouraged buying and supported price declines.
For the Quarter Ending June 2025
North America
• The Etoricoxib (USP) Price Index in North America experienced a sharp decline during June 2025, as aggressive export offers from Asia and softened regional demand drove Spot Price compression.
• Why did the price change in June 2025?
The price declined significantly due to reduced import costs, high inventory levels, and weak pharmaceutical sector offtake amid rising freight challenges.
• The Etoricoxib Spot Price continued to slide throughout the month as U.S. buyers postponed procurement, waiting for clearer pricing signals amid oversupply.
• The Etoricoxib Price Forecast for Q3 2025 signals sustained bearish pressure unless inventory levels reduce or downstream demand recovers in the pharmaceutical segment.
• The Etoricoxib Production Cost Trend remained favorable for importers, as Asian-origin suppliers offered discounted rates due to excess capacity and subdued global consumption.
• The Etoricoxib Demand Outlook weakened further as buyers limited activity to short-term needs, discouraged by ample stock and high shipping costs that reduced restocking urgency.
• Why did the price change in July 2025? The price decreased further in July 2025, driven by continued oversupply, poor restocking interest, and persistent downward pressure from low-cost Asian exports.
Europe
• The Price Index for Etoricoxib (USP) in Europe continued to slide in June 2025, with CFR Hamburg prices falling to USD 70,895, marking a steep decline of 11.48% month-over-month.
• Why did the price change in June 2025?
Prices dropped sharply due to aggressive Asian export offers, high domestic inventory levels, and subdued restocking activity in Germany's pharmaceutical sector.
• The Etoricoxib Spot Price weakened amid growing competition from low-cost imports and heavy price undercutting by both domestic and international suppliers aiming to clear excess stock.
• The Etoricoxib Price Forecast for July 2025 pointed to continued downside risks, driven by buyer conservatism, soft demand outlook, and ample inventory across the European market.
• The Etoricoxib Production Cost Trend remained low due to favorable import conditions—driven by a depreciating U.S. Dollar against the Euro and easing raw material prices globally.
• The Etoricoxib Demand Outlook was underwhelming, as pharmaceutical and healthcare sectors slowed procurement in response to weak end-user consumption, inventory overhang, and elevated freight costs from Asia.
• Why did the price change in July 2025? Prices decreased further in July 2025 as buyer resistance intensified, inventory liquidation continued, and sluggish downstream demand failed to absorb available stock.
APAC
• The Price Index in APAC exhibited a continued downward trend in July 2025, marking the fourth consecutive monthly decline in Etoricoxib prices across China’s export market.
• Etoricoxib Spot Price for Etoricoxib (USP) FOB Shanghai dropped to USD 70,800 in July, representing a decrease from June levels amid sustained bearish fundamentals.
• The Price Forecast for Q3 2025 indicates an overall weak pricing environment in APAC, with further downside risks expected due to persistent inventory overhang and fragile export demand.
• Etoricoxib Production Cost Trend remained favorable for suppliers, as input prices declined for the fifth month in a row, driven by easing pharmaceutical intermediates and energy costs.
• Etoricoxib Demand Outlook remained muted throughout July in APAC, particularly in China, with limited offtake from global buyers, prolonged destocking in overseas markets, and restrained procurement activity from international pharmaceutical formulators.
• Why did the price change in July 2025 – decrease: Etoricoxib prices in APAC declined due to high inventory levels, aggressive price reductions by exporters, and the continuation of subdued overseas demand, particularly in the US and EU.
• Etoricoxib Export competitiveness weakened further due to currency volatility and elevated freight charges, narrowing margins for Chinese exporters and prompting further price concessions.
• Inventory levels remained elevated across production hubs, with limited signs of improvement in warehouse offload rates, prompting sellers to prioritize liquidity through discount-led strategies.
• Regional cues such as continued softness in South Asia and limited import interest from ASEAN buyers compounded the oversupply scenario in China’s export corridors.
• Etoricoxib Price forecasts for Q3 2025 suggest a stable-to-soft trend, with downward bias likely to persist unless major restocking triggers emerge in Western markets.
For the Quarter Ending March 2025
North America
The U.S. Etoricoxib market showed gradual price increases during Q1 2025, reflecting a balance of supply constraints, stable demand, and rising raw material costs. January 2025 began with a modest price increase of +0.2%, driven by consistent pharmaceutical sector activity and supply conditions that remained relatively unchanged. The increase was supported by stable international demand and systematic inventory management by importers, allowing for a slight price appreciation amidst a generally stable market.
By February, the price trend continued upward, influenced by tighter supply conditions, rising production costs, and a 10% tariff on Chinese imports, which further escalated procurement expenses. Slow supplier deliveries and a decline in inventory levels further tightened the supply environment, intensifying competition among buyers. At the same time, demand for Etoricoxib surged modestly, driven by a recovery in industrial activity and stronger consumer sentiment. This combination of supply constraints and heightened buyer activity supported a moderate price increase throughout February.
In March, prices edged up again, as tight supply conditions and rising raw material costs continued to exert upward pressure on the market. The ongoing trade-related uncertainties, along with the 10% tariff and retaliatory measures from China, compounded the situation, driving up procurement costs. Despite easing logistics costs, the overall market sentiment remained positive, supported by steady demand from pharmaceutical sectors. The market closed Q1 with steady dynamics, reflecting a balanced interplay of demand, supply-side limitations, and pricing pressures.
Overall, the North American Etoricoxib market in Q1 2025 saw a series of moderate price increases, driven by consistent demand patterns, supply chain challenges, and rising raw material costs, with the tariff situation adding an extra layer of complexity to procurement strategies.
Asia Pacific
In Q1 2025, the Etoricoxib (USP) market in China showed moderate price increases, reflecting a stable yet cautiously managed environment. January saw a slight uptick of +0.2%, driven by steady demand from the pharmaceutical sector, which relies heavily on high-quality USP-grade Etoricoxib. The price increase was primarily attributed to regulatory compliance costs, balanced against controlled production output and domestic manufacturers' commitment to fulfilling both local and international orders. The market remained steady, supported by consistent demand for Etoricoxib from pharmaceutical formulators and adherence to stringent quality control protocols.
February experienced further price momentum due to multiple factors. The U.S. implementation of a 10% tariff on Chinese imports prompted bulk purchasing by international buyers, aiming to mitigate trade uncertainties. This, combined with rising raw material costs and increased demand for pharmaceutical excipients, intensified production expenses, exerting upward pressure on prices. A resurgence in China's Purchasing Managers' Index (PMI) further fueled demand from the pharmaceutical sector, driving up prices, despite a decline in freight costs that encouraged stronger export interest.
By March, the market saw a further slight increase in export prices, up 0.30%, as supply conditions tightened. Declining inventories, increased manufacturing activity, and rising input costs all contributed to the price rise. The 10% U.S. tariff and increased procurement activity ahead of potential trade disruptions further tightened supply chains. While China’s PMI indicated robust growth, which supported continued pharmaceutical sector demand, geopolitical uncertainties and higher tariffs continued to exert upward pressure on prices, especially in international markets.
Overall, the Q1 2025 trend in China for Etoricoxib (USP) was marked by gradual price increases driven by stable pharmaceutical demand, regulatory and production factors, and external trade dynamics. Both local and international market players faced pressure from rising costs and proactive procurement strategies, ensuring steady demand and sustained pricing strength throughout the quarter.
Europe
In Q1 2025, the German Etoricoxib market demonstrated modest yet consistent price increases, largely driven by a combination of supply-side constraints and steady demand from the pharmaceutical sector. January saw a slight uptick of 0.12%, as German buyers continued to maintain stable procurement activities despite anticipated disruptions due to the Lunar New Year holiday. This measured approach to purchasing, along with consistent demand from pharmaceutical manufacturers, contributed to incremental price adjustments. Suppliers responded to this steady inquiry flow, keeping production levels aligned with market needs while navigating logistical challenges, particularly in specialized pharmaceutical shipments.
The pricing trend continued in February, with a slight increase attributed to low inventory levels and rising procurement costs. The depreciation of the Euro against the U.S. Dollar and higher Etoricoxib prices from key exporting countries, such as China, further compounded cost pressures for German buyers. However, the strong demand from the pharmaceutical and healthcare sectors, bolstered by a recovery in industrial activity as indicated by Germany’s Manufacturing PMI, kept the price trajectory upwards. Despite some cost relief from lower freight rates, sustained demand from downstream industries continued to push prices higher throughout the month.
By March, the market saw another slight price increase, supported by continued cost pressures from upstream markets. Elevated production costs in China led to higher export prices, directly impacting German import values. Additionally, the German market benefited from a rebound in industrial activity, as reflected in the increase in Germany’s Manufacturing PMI, driving demand for Etoricoxib in pharmaceutical and nutraceutical applications. Despite some logistical relief from lower freight rates, the ongoing volatility of the Euro and strong origin market pricing ensured the persistence of upward pricing momentum throughout the month.
Overall, the first quarter of 2025 in Germany saw a stable and measured price increase in the Etoricoxib market. This trend was influenced by a combination of steady demand from the pharmaceutical sector, supply-side constraints, currency volatility, and geopolitical factors affecting trade flows. As the quarter progressed, these dynamics supported moderate price increases, reflecting the resilience of demand amid cost pressures in both domestic and international markets.
